Gene therapy of severe combined immunodeficiencies

Nature Reviews Immunology

Volumn 2, Issue 8, 2002, Pages 615-621

  Fischer, Alain ^a   Hacein Bey, Salima ^a   Cavazzana Calvo, Marina ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTOKINE; CYTOKINE RECEPTOR; RETROVIRUS VECTOR; ADENOSINE DEAMINASE; CYTOCHROME B;

BONE MARROW CELL; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HUMAN; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ANIMAL; GENETICS; IMMUNOLOGY;

ADENOSINE DEAMINASE; ANIMALS; CYTOCHROME B GROUP; GENE THERAPY; HUMANS; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES;

EID: 0036675793     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri859     Document Type: Review

References (63)

1. Fischer, A. Primary immunodeficiencies: an experimental model for molecular medicine Lancet 357, 1863-1869 (2001).
2. Buckley, R. H. et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 340, 508-516 (1999).
3. Haddad, E. et al. Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: a single center study of 22 patients. Blood 94. 2923-2930 (1999).
4. Patel, D. D. et al. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodefciency. N. Engl. J. Med. 342, 1325-1332 (2000).
5. Blaese, R. M. et al. T-lymphocyte-directed gene therapy for ADA-SCID: initial trial result after 4 years Science 270, 475-480 (1995).
6. Onodera, M. et al. Sucessful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 91, 30-36 (1998)
7. Bordignon, C. et al. Gene therapy in peripheral-blood lymphocytes and bone marrow for ADA-immunodeficient patients: gene therapy in peripheral-blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270, 470-475 (1995).
8. Kohn, D. B. et al. Engraftment of gene-modified umbilical-cord blood cells in neonates with adenosine deaminase deficiency. Nature Med. 1, 1017-1023 (1995).
9. Hoogerbrugge, P. M. et al. Bone-marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 3, 179-183 (1996).
10. Cavazzana-Calvo, M. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672 (2000).
11. Giblett, E. R., Anderson, J. E., Cohen, F., Pollara, B. & Meuwissen, H. J. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2, 1087-1089 (1972).
12. Valerio, D. et al. Cloning of human adenosine deaminase cDNA and expression in mouse cells. Gene 31, 147-153 (1984).
13. Miller, A. D. Retroviral vectors. Curr. Top. Microbiol. Immunol. 158, 1-24 (1992).
14. Ferrari, G. et al. An in vivo model of somatic-cell gene therapy for human severe combined immunodeficiency Science 251, 1363-1366 (1991).
15. Hershfield, M. S. Adenosine deaminase deficiency: clinical expression, molecular basis and therapy. Semin. Hematol. 4, 291-298 (1998).
16. + cells in ADA-deficient SCID neonates. Nature Med. 4, 775-780 (1998).
17. Aiuti, F. et al. Immune reconstitution after PBL gene therapy in ADA-deficient SCID: the impact of discontinuation of enzyme replacement therapy. Nature Med. 8, 423-425 (2002).
18. Blackburn, M. R., Knudsen, T. B. & Kellems, R. E. Genetically engineered mice demonstrate that adenosine deaminase is essential for early postimplantation development. Development 124, 3089-3097 (1997).
19. Blackburn, M. R. Datta S. K. & Kellems, R. E. Adenosine deaminase deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J. Biol. Chem. 273, 5093-5098 (1998).
20. Anderson, D. C. & Springer, T. A. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1 and p150,95 glycoproteins. Annu. Rev. Med. 38, 175-194 (1987).
21. Segal, B. H., Leto, T. L., Gallin, J. I., Malech, H. L. & Holland, S. M. Genetic, biochemical and clinical features of chronic granulomatous disease. Medicine 79, 170-200 (2000).
22. Bauer, T. R. Jr & Hickstein, D. D. Gene therapy for leukocyte adhesion deficiency. Curr Opin. Mol. Ther. 2, 383-388 (2000).
23. Dinauer, M. C., Li, L. L., Biorgvinsdottirh, H., Ding, C. & Pech, N. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-inked chronic granulomatous disease. Blood 94, 914-922 (1999).
24. Mardiney, M. III, Jackson, S. H., Spratt, S. K., Li, F., Holland, S. M. & Malech, H. L. Enhanced host defense after gene transfer in the murine p47 phox-deficient model of chronic granulomatous disease. Blood 89, 2268-2275 (1997).
25. + cells derived from a patient with leukocyte adhesion deficiency type 1. Blood 91, 1520-1526 (1998).
26. Malech, H. L. et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl Acad. Sci. USA 94, 12133-12138 (1997).
27. Malech, H. L. Use of serum-free medium with fibronectin fragment enhanced transduction in a system of gas-permeable plastic containers to achieve high levels of retrovirus transduction at clinical scale. Stem Cells 18, 155-156 (2000).
28. Dinauer, M. C., Lekstrom-Himes, J. A. & Dale, D. C. Inherited neutrophil disorders: molecular basis and new therapies. Hematology 303-318 (2000).
29. Kiem, H. P. et al. Gene transfer into marrow repopulating cells: comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons. Blood 90, 4638-4645 (1997).
30. Hanenberg, H. et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nature Med. 2, 876-882 (1996).
31. Noguchi, M. et al. Interleukin-2 receptor γ-chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147-157 (1993)
32. Macchi, P. et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65-68 (1995).
33. Russell, S.M. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797-800 (1995).
34. + severe combined immunodeficiency. Nature Genet. 20, 394-397 (1998).
35. Leonard, W. J. Cytokines and immunodeficiency diseases. Nature Rev. Immunol. 1, 200-208 (2001).
36. Stephan, V. et al. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N. Engl. J. Med. 335, 1563-1567 (1996).
37. Bousso, P. et al. Diversity, functionality and stability of the T-cell repertoire derived in vivo from a single human T-cell precursor Proc. Natl. Acad. Sci. USA 97, 274-278 (2000).
38. Bunting, K. D., Sangster, M. Y., Ihle, J. N. & Sorrentino, B. P. Restoration of lymphocyte function in Janus kinase-3-deficient mice by retroviral-mediated gene transfer. Nature Med. 4, 58-64 (1998).
39. Bunting, K., Lu, T., Kelly, P. F. & Sorrentino, B. P. Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloblation. Hum. Gene Ther. 11, 2353-2364 (2000).
40. Lo, M. et al. Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach. Blood 94, 3027-3038 (1999).
41. Soudais, C. et al. Stable and functional lymphoid reconstitution of common cytokine receptor γ-chain-deficient mice by retroviral-mediated gene transfer. Blood 95, 3071-3077 (2000).
42. Otsu, M. et al. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem-cell gene therapy. Mol. Ther. 1, 145-153 (2000).
43. Candotti, F., Johnston, J. A., Puck, J. M., Sugamura, K., O'Shea, J. J. & Blaese, R. M. Retroviral-mediated gene correction for X-linked severe combined immunodeficiency. Blood 87, 3097-3102 (1996).
44. Taylor, N. et al. Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the γc gene. Blood 87, 3103-3107 (1996).
45. Hacein-Bey, S. et al. γc gene transfer into SCID-X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood 87, 3108-3116 (1996)
46. Cavazzana-Calvo, M. et al. Role of interleukin-2 (IL-2), IL-7 and IL-15 in natural killer cell differentiation from cord-blood hematopoietic progenitor cells and from γc-transduced severe combined immunodeficiency X1 bone-marrow cells. Blood 88, 3901-3909 (1996).
47. Hacein-Bey, S., Basile, G. D., Lemerle, J., Fischer, A. & Cavazzana-Calvo, M. γc gene transfer in the presence of stem-cell factor, FLT-3L, interleukin-7 (IL-7), IL-1 and IL-15 cytokines restores T-cell differentiation from γc X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ cultures. Blood 92, 4090-4097 (1998).
48. Hacein-Bey-Abina, S. et al. Sustained correction of human X-linked severe combined immunodeficiency (SCID-X1) by ex vivo gene therapy. N. Engl. J. Med. 346, 1185-1193 (2002).
49. Kondo, M., Weissman I. L. & Akashi, K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91, 661-672 (1997).
50. Hao, Q. L. et al. Identification of a novel, human multilymphoid progenitor in cord blood. Blood 97, 3683-3690 (2001).
51. Hirschhorn, R. et al. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nature Genet. 13, 290-295 (1996).
52. Schwarz, K. et al. RAG mutations in human B-cell-negative SCID. Science 274, 97-99 (1996).
53. Moshous, D. et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 105, 177-186 (2001)
54. Wada, T. et al. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc. Natl Acad. Sci. USA 98, 8697-8702 (2001).
55. Snapper, S. B. & Rosen, F. S. The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization. Annu. Rev. Immunol. 17, 905-929 (1999).
56. Sorrentino, B. P. et al. Selection of drug-resistant bone-marrow cells in vivo after retroviral transfer of human MDR-1. Science 257, 99-103 (1992).
57. Bonini, C. et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724 (1997).
58. Qin, G. et al. Preselective gene therapy for Fabry disease Proc. Natl Acad. Sci. USA 98, 3428-3433 (2001).
59. Kelly, P. F., Vandergriff, J., Nathwani, A., Nienhuis, A. W. & Vanin, E. F. Highly efficient gene transfer into cord-blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) enveloppe protein. Blood 96, 1206-1214 (2000).
60. Halene, S. et al. Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. Blood 94, 3349-3357 (1999).
61. Sadelain, M., Frassoni, F. & Riviere, I. Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells. Curr. Opin. Hematol. 7, 364-377 (2000).
62. May, C. et al. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivrirus-encoded human β-globin. Nature 406, 82-86 (2000).
63. Aiuti, A. et al. Correction of ADA-SCID by stem-cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413 (2002).